JW (Cayman) Therapeutics Co. Ltd
JWCTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $158,218 | $173,856 | $145,702 | $30,797 |
| % Growth | -9% | 19.3% | 373.1% | – |
| Cost of Goods Sold | $80,902 | $85,637 | $86,946 | $21,752 |
| Gross Profit | $77,316 | $88,219 | $58,756 | $9,045 |
| % Margin | 48.9% | 50.7% | 40.3% | 29.4% |
| R&D Expenses | $282,989 | $413,616 | $407,818 | $414,397 |
| G&A Expenses | $44,548 | $64,501 | $179,763 | $201,518 |
| SG&A Expenses | $145,163 | $117,751 | $370,640 | $372,250 |
| Sales & Mktg Exp. | $100,615 | $53,250 | $190,877 | $170,732 |
| Other Operating Expenses | $108,445 | $346,459 | $136,181 | -$18,519 |
| Operating Expenses | $536,597 | $877,826 | $914,639 | $768,128 |
| Operating Income | -$459,281 | -$789,607 | -$855,883 | -$759,083 |
| % Margin | -290.3% | -454.2% | -587.4% | -2,464.8% |
| Other Income/Exp. Net | -$131,343 | $21,611 | $9,748 | $56,755 |
| Pre-Tax Income | -$590,624 | -$767,996 | -$846,135 | -$702,328 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$590,624 | -$767,996 | -$846,135 | -$702,328 |
| % Margin | -373.3% | -441.7% | -580.7% | -2,280.5% |
| EPS | -1.43 | -1.87 | -2.06 | -1.76 |
| % Growth | 23.5% | 9.2% | -17% | – |
| EPS Diluted | -1.43 | -1.87 | -2.06 | -1.76 |
| Weighted Avg Shares Out | 413,634 | 411,530 | 410,093 | 399,749 |
| Weighted Avg Shares Out Dil | 413,634 | 411,530 | 410,093 | 399,749 |
| Supplemental Information | – | – | – | – |
| Interest Income | $28,431 | $34,026 | $16,535 | $8,296 |
| Interest Expense | $12,220 | $12,415 | $6,787 | $2,692 |
| Depreciation & Amortization | $89,663 | $99,834 | $87,074 | $33,013 |
| EBITDA | -$488,741 | -$655,747 | -$752,274 | -$738,703 |
| % Margin | -308.9% | -377.2% | -516.3% | -2,398.6% |